Intravitreal Bevacizumab for Age-Related Macular Degeneration

Phase 2TerminatedNCT00347165

Asociación para Evitar la Ceguera en México50 enrolled

Overview

The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Age Related Macular Degeneration

Interventions

bevacizumab intravitreal injectionDRUG

Eligibility

Sex: ALLMin age: 50 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \>50 age related macular degeneration Exclusion Criteria: * moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease

Locations (1)

Hospital Luis Sanchez Bulnes

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Improvement of visual acuity at 6 months

Secondary Outcomes

Retinal thickness at 6 months

Leakiness in fluorangiography at 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.